Abstract
Background
Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD) as well as with an increased risk of chronic kidney disease (CKD), also a known cardiovascular risk factor. However, it is not known if RA is a predictor of adverse outcomes in patients with CKD. We hypothesized that among a cohort of patients with CKD, RA would be associated with an increased risk of mortality.
Materials and methods
We conducted a retrospective study of 3939 participants with CKD from the prospective Chronic Renal Insufficiency Cohort (CRIC) study. The primary outcome of interest was all-cause mortality. Secondary outcomes included CKD progression (defined as end-stage kidney disease or 50% decline in estimated glomerular filtration rate), cardiovascular endpoints, and composite of myocardial infarction, cerebrovascular accident, heart failure, or death. Multivariable Cox proportional hazards regression was utilized, adjusting for potential confounders including age, sex, race/ethnicity, body mass index, current smoker, and education.
Results
The study cohort included 83 participants with RA on a disease modifying anti-rheumatic drug (DMARD). In the adjusted analysis, CKD-RA status was significantly associated with an increased risk of death (adjusted HR, aHR, 1.73 (1.27, 2.35)) and composite outcome (aHR 1.65 (1.27–2.15)) even after adjusting for traditional risk factors. Similar statistically significant associations were observed between CKD-RA and other secondary outcomes except for CKD progression.
Conclusion
RA was associated with higher mortality among individuals with CKD but not progressive renal decline. Further studies evaluating the mechanisms behind this association are needed.
Key Points • Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD) as well as with an increased risk of chronic kidney disease (CKD), also a known cardiovascular risk factor. However, it is not known if RA is an independent predictor of adverse outcomes in patients with CKD • In this study, we observed that CKD patients with RA experience higher mortality as well as an increased risk of CVD compared to patients with CKD without comorbid RA • These data provide rationale for more aggressive monitoring for CVD in patients with CKD and RA. They also underscore the need for determining which interventions can help decrease the burden of mortality in these patients |
Similar content being viewed by others
References
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71(9):1524–1529
Blum A, Adawi M (2019) Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 18(7):679–690
Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y (2018) Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 71(3):277–283
Fragoulis GE, Panayotidis I, Nikiphorou E (2020) Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 18(5):431–446
Davis JM III, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2008) The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 58(9):2603–2611
Giles JT, Simon LS, Pope J, Paik JS, Grabner M, Quebe A, Kannowski CL, Salinas CA, Curtis JR (2021) Prevalence of renal impairment in a US commercially insured rheumatoid arthritis population: a retrospective analysis. Rheumatol Ther 8(3):1383–1391
Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL et al (2003) The chronic renal insufficiency cohort (CRIC) study: design and methods. J Am Soc Nephrol 14(7 Suppl 2):S148-153
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J et al (2009) Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4(8):1302–1311
Formica MK, McAlindon TE, Lash TL, Demissie S, Rosenberg L (2010) Validity of self-reported rheumatoid arthritis in a large cohort: results from the Black Women’s Health Study. Arthritis Care Res 62(2):235–241
Bansal N, McCulloch CE, Lin F, Alper A, Anderson AH, Cuevas M, Go AS, Kallem R, Kusek JW, Lora CM et al (2017) Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC study (chronic renal insufficiency cohort). Hypertension 70(2):435–443
Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane MG, Mohler E, Ojo A et al (2016) Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 315(20):2200–2210
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303–1307
Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697
Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26(5 Suppl 51):S35-61
Zhang C (2008) The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 103(5):398–406
Alemao E, Bao Y, Weinblatt ME, Shadick N (2020) Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs: results from a real-world study. Arthritis Care Res (Hoboken) 72(2):176–183
Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ (2005) Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 52(8):2293–2299
Blake GJ, Ridker PM (2001) Novel clinical markers of vascular wall inflammation. Circ Res 89(9):763–771
Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18):2165–2168
Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103(9):1194–1197
Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, Shlipak MG (2010) Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 25(1):119–124
Ortega O, Rodriguez I, Gallar P, Carreño A, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Vigil A (2002) Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17(6):1105–1109
Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS (2002) Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int 62(6):2208–2215
Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68(1):237–245
Cheng YJ, Cheng XY, Zhang YM, Wang F, Wang X, Meng LQ, Liu G, Cui Z, Zhao MH (2022) Effects ofhydroxychloroquine on proteinuria in membranous nephropathy. J Nephrol 35(4):1145–1157
Rodrigues JC, Bargman JM (2018) Antimalarial drugs for the prevention of chronic kidney disease in patients with rheumatoid arthritis: the importance of controlling chronic inflammation? Clin J Am Soc Nephrol 13(5):679–680
Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489
Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47(1):72–75
del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A (2014) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 66(2):264–272
Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56(3):820–830
Movahedi M, Costello R, Lunt M, Pye SR, Sergeant JC, Dixon WG (2016) Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. Eur J Epidemiol 31(10):1045–1055
Mantel Ä, Holmqvist M, Andersson DC, Lund LH, Askling J (2017) Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 69(10):1275–1285
Aslam F, Bandeali SJ, Khan NA, Alam M (2013) Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res (Hoboken) 65(4):534–543
Fan F, Galvin A, Fang L, White DA, Moore XL, Sparrow M, Cicuttini F, Dart AM (2014) Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) 11(1):29
Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271
Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL, Therneau TM, Gabriel SE (2011) The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 38(8):1601–1606
Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, Lin WC, Cheng YP, Tsai TF, Ho SY (2015) Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications - a national population-based cohort study. PLoS ONE 10(9):e0136508
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732
Acknowledgements
The Chronic Renal Insufficiency Cohort Study (CRIC) was conducted by the CRIC Study Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CRIC reported here were supplied by the NIDDK Central Repositories. This manuscript was not prepared in collaboration with Investigators of the CRIC study and does not necessarily reflect the opinions or views of the CRIC study, the NIDDK Central Repositories, or the NIDDK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This study was presented as a poster at the EULAR 2021 virtual Congress. Citation: Ann Rheum Dis, volume 80, supplement 1, year 2021, page 476.
Rights and permissions
About this article
Cite this article
Ezeanuna, M., Prince, D., Alexander, S. et al. Association of rheumatoid arthritis with mortality in chronic kidney disease: a cohort study. Clin Rheumatol 41, 2669–2676 (2022). https://doi.org/10.1007/s10067-022-06223-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-022-06223-x